- The FDA has signed off Anixa Biosciences Inc's ANIX application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, developed in partnership with Moffitt Cancer Center.
- Anixa Biosciences has an exclusive worldwide license to the technology. The therapeutic product includes engineered T-cells that target the follicle-stimulating hormone receptor (FSHR).
- FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries.
- Related content: Benzinga's Full FDA Calendar
- Price Action: ANIX stock is up 4.76% at $5.50 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareFDAMoversTrading IdeasGeneralBriefsOvarian CancerPhase 1 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
